Eteplirsen

證據等級: L5

預測適應症: 10 個

Eteplirsen: From Exon 51-Skip-Amenable DMD to Duchenne and Becker Muscular Dystrophy

One-Sentence Summary

Eteplirsen (Exondys 51) is an antisense oligonucleotide originally developed and approved for Duchenne muscular dystrophy (DMD) patients whose dystrophin gene mutations are amenable to exon 51 skipping. The TxGNN model’s top prediction — Duchenne and Becker muscular dystrophy — is not a novel repurposing signal but a confirmation of the drug’s own core indication, supported by 12 clinical trials and 19 publications, including two pivotal Phase 3 studies.

Quick Overview

Item	Content
Original Indication	Not marketed in Taiwan (no NDA on file); per trial/mechanistic evidence, approved use is DMD amenable to exon 51 skipping
Predicted New Indication	Duchenne and Becker muscular dystrophy
TxGNN Prediction Score	99.95%
Evidence Level	L1
US Market Status	Not Marketed (Taiwan)
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed DrugBank-sourced MOA text is not yet available (data gap), but the mechanism is well documented in the clinical evidence itself. Eteplirsen is a phosphorodiamidate morpholino oligomer (PMO) that binds dystrophin pre-mRNA and induces skipping of exon 51. In patients with frame-shift deletions near this region, this restores the reading frame and enables production of a truncated but partially functional dystrophin protein — the underlying deficiency in DMD.

Critically, the TxGNN “predicted” indication of Duchenne and Becker muscular dystrophy is not a cross-indication extrapolation: it is essentially the drug’s own approved therapeutic niche (exon 51 skip-amenable mutations, ~13% of the DMD population). Becker muscular dystrophy shares the same dystrophin gene defect in a milder phenotype, so the mechanistic rationale extends naturally to that population.

Because the prediction converges with the drug’s real-world indication, this case functions more as a validation check on the model than a genuine repurposing opportunity — evidence strength is high, but the “new use” framing should be interpreted cautiously.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01396239	Phase 2	Completed	12	Randomized, double-blind, placebo-controlled dose study (30/50 mg/kg) over 24 weeks in ambulant DMD subjects
NCT03992430	Phase 3	Active, not recruiting	160	Randomized, double-blind comparison of high-dose (100/200 mg/kg) vs. standard 30 mg/kg eteplirsen in exon 51 skip-amenable DMD
NCT02255552	Phase 3	Completed	109	Open-label, multi-center pivotal trial with untreated control arm; key efficacy evidence supporting FDA accelerated approval
NCT00844597	Phase 1/2	Completed	19	First-in-human IV safety study of AVI-4658 (eteplirsen) in exon 51 skip-amenable DMD
NCT01540409	Phase 2	Completed	12	Open-label extension (212 additional weeks) evaluating ongoing efficacy, safety and biomarker correlation
NCT02286947	Phase 2	Completed	24	Safety and tolerability in advanced-stage DMD patients amenable to exon 51 skipping
NCT02420379	Phase 2	Completed	33	Safety, efficacy, tolerability and PK in early-stage DMD
NCT03218995	Phase 2	Completed	15	Safety, tolerability and PK of weekly IV eteplirsen in very young patients (6–48 months)
NCT06606340	Phase 4 (N/A)	Enrolling by invitation	300	Long-term real-world observational study of eteplirsen, golodirsen and casimersen in routine practice
NCT04179409	Phase 2	Completed	3	Comparative efficacy/safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 across exon 45/51/53 duplications (small sample)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
23907995	2013	Double-blind placebo-controlled study	Annals of Neurology	Pivotal report testing eteplirsen’s ability to induce dystrophin production and improve 6-minute walk distance
34120909	2021	Cohort (Open-label extension)	J Neuromuscul Dis	PROMOVI trial: Phase 3, multicenter, open-label efficacy/safety results in a larger DMD cohort (30 mg/kg/week x 96 weeks)
38669554	2024	Systematic Review/Meta-Analysis	J Neuromuscul Dis	Predictors of loss of ambulation in DMD
40831143	2026	Cohort	J Neuromuscul Dis	Propensity-matched analysis of LVEF decline comparing eteplirsen-treated vs. control DMD patients
29254734	2018	Pooled Analysis	J Clin Neurosci	Pooled analysis of eteplirsen outcomes in paediatric DMD patients
38482981	2024	Cohort	Muscle & Nerve	Survival among patients receiving eteplirsen up to 8 years, contextualized against natural history controls
37207382	2023	Open-label dose-escalation study	Neuromuscular Disorders	Safety, tolerability and PK of eteplirsen in boys aged 6–48 months (NCT03218995)
40308063	2025	Review	Molecular Therapy	Clinical applications of exon-skipping ASOs (eteplirsen, golodirsen, viltolarsen, casimersen) in neuromuscular disease
28280301	2017	Review	Drug Des Devel Ther	Overview of eteplirsen’s accelerated FDA approval and treatment context
31794463	2019	Review	Continuum (Minneap Minn)	Broader review of dystrophinopathies including DMD/BMD management and emerging therapies

US Market Information

Eteplirsen is not currently marketed in this jurisdiction — 0 licenses/authorizations are on file, and market_status is recorded as “Not Marketed.” No NDA-level product detail is available to tabulate.

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data were not retrievable at this data cutoff (TFDA labeling not yet obtained — flagged as a blocking data gap).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Evidence level L1 is supported by multiple completed Phase 2/3 trials, including a pivotal controlled study (NCT02255552) that underpinned FDA accelerated approval, plus 19 supporting publications. However, this is effectively confirmation of eteplirsen’s existing approved indication rather than a new repurposing opportunity, and formal safety/labeling data for this jurisdiction is still missing.

To proceed, the following is needed:

TFDA (or local regulatory) label — warnings and contraindications (DG001, blocking)
Confirmed DrugBank/product MOA documentation (DG002)
Clarification that this candidate reflects label-consistent use rather than off-label repurposing, before any S1 safety review proceeds
Genotype confirmation requirement (exon 51 skip-amenable mutation) noted explicitly in any downstream guidance, since efficacy is restricted to that subgroup
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.